Agreed, timeline for results was a bit ambitious. When I read they were initially expecting results H1 2023 I thought it would be remarkable if they achieved that. The only gripe I have is perhaps Jon should’ve explained each age group having to be signed off before commencement. He may have explained that already so apologies if he has, but if you know the trials are structured where they have to sign off each age group and that will extend the timeline substantially over what has been quoted then he should’ve laid it out in the first instance.
This is a minor gripe, I expected delays. Trials never run on time (for the most part) so I’m not surprised by this announcement. Other than that everything looks pretty good to me: submission of IND for PW, good safety profile, no issues with cardiac tests. What’s curious is ROW deals are still positioned before Trof FDA approval on the timeline. Surely they could move it behind of approval without shareholder disgruntlement if they are waiting for FDA approval, I don’t think the market would care too much.. It’s onwards and upwards from here
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)